Age-specific control and Alzheimers disease reference curves and z-scores for glial fibrillary acidic protein in blood DOI Creative Commons
Steffen Halbgebauer, Badrieh Fazeli, Veronika Klose

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 5, 2024

Abstract Background Serum glial fibrillary acidic protein (GFAP) is a biomarker for astrocytic injury and astrogliosis. Concentrations are elevated in numerous neurological disorders, including pronounced increase Alzheimer’s disease (AD). However, GFAP levels the serum also with age. Consequently, integration of into clinical routine their interpretation demands age-adjusted reference values. Methods from 1273 subjects (952 non-inflammatory non-neurodegenerative controls 321 AD) were analyzed using microfluidic Ella system. Age-dependent values calculated by additive quantile regression analysis. Percentiles z-scores employed presentation as function Results All patients within AD continuum exhibited statistically comparison to control cohort (p<0.0001). This remained case when newly generated age-corrected applied In cohort, non-linear elevation increasing age was observed (Spearman correlation coefficient (r) 0.62, 95%CI 0.58-0.66, p<0.0001). contrast, more linear (0.16, 0.05-0.26, p=0.004). cut-offs different groups. The areas under curve (AUC 0.97) demonstrated excellent diagnostic test performance early onset group. effect less marked elderly 0.72). Conclusions Our novel enable practice, moving group individual level. They support both intra- interindividual single diseases pathology, an accurate discrimination disease.

Language: Английский

Establishing Normal Serum Values of Neurofilament Light Chains and Glial Fibrillary Acidic Protein Considering the Effects of Age and Other Demographic Factors in Healthy Adults DOI Open Access
Alexander Rodero-Romero, Enric Monreal,

Raquel Sainz-Amo

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(14), P. 7808 - 7808

Published: July 17, 2024

Multiple studies have shown the importance of blood-based biomarkers indicating axonal damage (serum neurofilament light chains [sNfL]) or astroglia activation glial fibrillary acidic protein [sGFAP]) for monitoring different neurological diseases. However, normal values these variables remain to be clearly defined, partly due influence demographic factors. We investigated differences in a cohort healthy volunteers. A cross-sectional study was conducted including 116 controls with ages between 18 and 69 years (67.5% females; n = 79). sNfL sGFAP concentrations were measured using single-molecule arrays. Age body mass index affected values, age found most important factor. The changed age, we established individuals younger than 45 as <10 pg/mL older <15 pg/mL. at individuals. Alternatively, Z-score 1.5 relevant all controls. only by age. Differences evident 55 years. highest normality limit 140 under 280 defined levels their corresponding age-associated changes. These data may contribute application such clinical practice.

Language: Английский

Citations

3
Comparison of Serum and Cerebrospinal Fluid Neurofilament Light Chain Concentrations Measured by Ella™ and Lumipulse™ in Patients with Cognitive Impairment DOI Creative Commons
Teresa Urbano, Riccardo Maramotti, Manuela Tondelli

et al.

Diagnostics, Journal Year: 2024, Volume and Issue: 14(21), P. 2408 - 2408

Published: Oct. 29, 2024

Objective: Neurofilament light chain proteins (NfLs) are considered a promising biomarker of neuroaxonal damage in several neurological diseases. Their measurement the serum and cerebrospinal fluid (CSF) patients with dementia may be especially useful. Our aim was to compare NfL performance two advanced technologies, specifically Ella™ microfluidic platform Lumipulse™ fully automated system, cognitive disorders. Methods: Thirty subjects neurodegenerative disorders (10 Alzheimer’s Disease, 10 Frontotemporal Dementia, non-progressive Mild Cognitive Impairment) seen at Neurology Clinic Modena University Hospital (Italy) underwent CSF both (Bio-Techne, Minneapolis, MN, USA)) system for CLEIA (Fujirebio Inc., Ghent, Belgium). Correlation regression analyses were applied assess association between concentrations obtained assays serum. The Passing–Bablok method employed evaluate agreement assays. Results: There high correlations (r = 0.976, 95% CI. 0.950–0.989 vs. r 0.923, CI 0.842–0.964 serum). A model estimated explain relationship assays, allowing us switch from one other when only assay available. Conclusions: We found good degree correlation methods neurocognitive also established that will allow comparisons results either technique, meta-analyses larger sample sizes.

Language: Английский

Citations

3
Navigating the Alzheimer’s Biomarker Landscape: A Comprehensive Analysis of Fluid-Based Diagnostics DOI Creative Commons

Elsa El Abiad,

Ali Al-Kuwari,

Ubaida Al-Aani

et al.

Cells, Journal Year: 2024, Volume and Issue: 13(22), P. 1901 - 1901

Published: Nov. 18, 2024

Alzheimer's disease (AD) affects a significant portion of the aging population, presenting serious challenge due to limited availability effective therapies during its progression. The advances rapidly, underscoring need for early diagnosis and application preventative measures. Current diagnostic methods AD are often expensive invasive, restricting access general public. One potential solution is use biomarkers, which can facilitate detection treatment through objective, non-invasive, cost-effective evaluations AD. This review critically investigates function role biofluid biomarkers in detecting AD, with specific focus on cerebrospinal fluid (CSF), blood-based, saliva biomarkers.

Language: Английский

Citations

1
Prominent Perspective on Existing Biological Hallmarks of Alzheimer’s Disease DOI
Namrata Singh, Srishti Sharma, Kallol K. Ghosh

et al.

Current Topics in Medicinal Chemistry, Journal Year: 2024, Volume and Issue: 24(13), P. 1120 - 1133

Published: April 9, 2024

Biomarkers are the most significant diagnosis tools tending towards unique approaches and solutions for prevention cure of Alzheimer's Disease (AD). The current report provides a clear perception concept various biomarkers their prominent features through analysis to provide possible solution inhibition events in AD. Scientists around world truly believe that crucial hallmarks can serve as critical early diagnosis, cure, prevention, well future medicine. awareness understanding such would puzzled mechanism this neuronal disorder. Some argued present article still an experimental phase they need undergo specific clinical trials before be considered treatment.

Language: Английский

Citations

0
Age-specific control and Alzheimers disease reference curves and z-scores for glial fibrillary acidic protein in blood DOI Creative Commons
Steffen Halbgebauer, Badrieh Fazeli, Veronika Klose

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 5, 2024

Abstract Background Serum glial fibrillary acidic protein (GFAP) is a biomarker for astrocytic injury and astrogliosis. Concentrations are elevated in numerous neurological disorders, including pronounced increase Alzheimer’s disease (AD). However, GFAP levels the serum also with age. Consequently, integration of into clinical routine their interpretation demands age-adjusted reference values. Methods from 1273 subjects (952 non-inflammatory non-neurodegenerative controls 321 AD) were analyzed using microfluidic Ella system. Age-dependent values calculated by additive quantile regression analysis. Percentiles z-scores employed presentation as function Results All patients within AD continuum exhibited statistically comparison to control cohort (p<0.0001). This remained case when newly generated age-corrected applied In cohort, non-linear elevation increasing age was observed (Spearman correlation coefficient (r) 0.62, 95%CI 0.58-0.66, p<0.0001). contrast, more linear (0.16, 0.05-0.26, p=0.004). cut-offs different groups. The areas under curve (AUC 0.97) demonstrated excellent diagnostic test performance early onset group. effect less marked elderly 0.72). Conclusions Our novel enable practice, moving group individual level. They support both intra- interindividual single diseases pathology, an accurate discrimination disease.

Language: Английский

Citations

0